Aspirin Resistance Clinical Trial
Official title:
Mechanism Based Resistance to Aspirin
The purpose of this research is to study why some people do not respond to the benefits of aspirin therapy. The benefit of aspirin is cardioprotection, or decreasing the risk of heart attack and/or stroke. Aspirin works by disabling the platelets, part of the blood cells used in clotting, from sticking together and forming blood clots, thus protecting the heart. It has been observed that failure to respond to aspirin therapy occurs in about 10% of the general population and that despite taking aspirin everyday, this group of non- responders is not getting protection for their heart. The investigators would like to determine why and how this happens.
n/a
Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01432652 -
The Efficacy of Aspirin in the Postoperative Period in Vascular Surgery
|
N/A | |
| Unknown status |
NCT01935193 -
Aspirin Resistance Reversibility in Diabetic Patients
|
Phase 4 | |
| Not yet recruiting |
NCT01547039 -
Platelet Reactivity and MES During CEA
|
N/A | |
| Completed |
NCT01159639 -
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting
|
Phase 4 | |
| Completed |
NCT00792272 -
Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients
|
N/A | |
| Completed |
NCT00466154 -
The Effect of Serum LDL Lowering on Aspirin Resistance
|
N/A | |
| Completed |
NCT01104441 -
Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia
|